Economic evaluation of hepatocellular carcinoma surveillance in chronic hepatitis B patients with virological remission.

ABSTRACT:

Background

Subsequent risk of hepatocellular carcinoma (HCC) persists in chronic hepatitis B (CHB) patients with virological remission. We aimed to assess the cost-effectiveness of HCC surveillance in those patients and determine appropriate age to commence or discontinue surveillance.

Methods

We developed an individual-based state transition model, simulating the advancement of HCC in CHB patients with virological remission. We used this model to compare the incremental cost-effectiveness ratio (ICER) and long-term health outcomes of biannual or annual HCC surveillance for varying durations with no surveillance.

Results

For compensated cirrhosis patients with CHB, biannual surveillance was not cost-effective for all age groups, while annual surveillance was cost-effe

SUBMITTER: Fang K 

PROVIDER: S-EPMC11323655 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature